Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off

Movement Disorders

Volumn 22, Issue 11, 2007, Pages 1550-1555

  Deuschl, Günther ^a   Vaitkus, Antanas ^b   Fox, Gabriele Cornelia ^c,d   Roscher, Torsten ^c,d   Schremmer, Dieter ^e   Gordin, Ariel ^c,d  

^a UNIVERSITY OF KIEL   (Germany)

^b KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

^c Medical Department   (Germany)

^d Medical Department   (Finland)

^e GKM   (Germany)

Author keywords

Cabergoline; Clinical trial; COMT inhibition; Entacapone; Parkinson's disease; Wearing off

Indexed keywords

CABERGOLINE; ENTACAPONE; LEVODOPA;

AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; FATIGUE; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARKINSONISM; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SLEEP DISORDER; SOMNOLENCE; STATISTICAL ANALYSIS; TREATMENT RESPONSE; TREMOR; VERTIGO; XEROSTOMIA;

AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; CATECHOLS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; DYSKINESIAS; ERGOLINES; FEMALE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; NITRILES; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES;

EID: 34748926549     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21473     Document Type: Article

References (21)

1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
2. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
3. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. A randomized controlled trial. JAMA 2000;284:1931-1938.
4. Horstink M, Tolosa E, Bonucelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: Late (complicated) Parkinson's disease. Eur J Neurol 2006;13:1186-1202.
5. Eggert KM, Deuschl G, Gasser T, et al. Parkinson-syndrome. In: Diener HC, Putzki N, Berlit P, editors. Leitlinien für Diagnostik und Therapie in der Neurologie (Guidelines of the German Society of Neurology). Stuttgart: Thieme; 2005. p 48-71.
6. Rascol O, Brooks DJ, Korczyn AD, DeDeyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-1491.
7. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to sinemet in Parkinson's disease. Mov Disord 1994;9:40-47.
8. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-755.
9. Koller W, Lees A, Doder M, Hely M, and the Tolcapone/Pergolide Study Group. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov Disord 2001;16:858-866.
10. Curran MP, Perry CM. Cabergoline: a review of its use in the treatment of Parkinson's disease. Drugs 2004;64:2125-2141.
11. Gordin A, Kaakkola S, Teravainen H. Position of COMT inhibition in the treatment of Parkinson's disease. Adv Neurol 2003;91:237-250.
12. Tolcapone Study Group. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Mov Disord 1999;14:38-44.
13. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-539.
14. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's disease rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan; 1987. p 153-163.
15. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
16. Jenkinson C, Peto V, Fitzpatrick R, Greenhall R, Hyman N. Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the short-form health survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39). Age Ageing 1995;24:505-509.
17. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995;4:241-248.
18. Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998;51:1309-1314.
19. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105:245-255.
20. Steiger MJ, El-Debas T, Anderson T, Findley LJ, Marsden CD. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 1996;243:68-72.
21. Peto V, Jenkinson C, Fitzpatrick R. Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire. Age Ageing 2001;30:299-302.